Zynex (ZYXI) Projected to Post Quarterly Earnings on Wednesday

Zynex (NASDAQ:ZYXI - Get Free Report) is expected to be releasing its Q2 2025 earnings data before the market opens on Wednesday, July 23rd. Analysts expect Zynex to post earnings of ($0.20) per share and revenue of $27.38 million for the quarter.

Zynex (NASDAQ:ZYXI - Get Free Report) last issued its earnings results on Monday, April 28th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.09). The firm had revenue of $26.58 million during the quarter, compared to analysts' expectations of $30.83 million. Zynex had a negative return on equity of 23.70% and a negative net margin of 4.30%. On average, analysts expect Zynex to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zynex Price Performance

ZYXI traded up $0.13 during midday trading on Thursday, hitting $2.40. The stock had a trading volume of 59,432 shares, compared to its average volume of 224,093. The company has a debt-to-equity ratio of 2.87, a quick ratio of 2.63 and a current ratio of 3.46. Zynex has a 1 year low of $1.66 and a 1 year high of $10.62. The business has a fifty day moving average of $2.32 and a 200 day moving average of $4.27. The company has a market cap of $72.60 million, a P/E ratio of -10.00 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective on shares of Zynex in a research report on Monday, June 30th. Royal Bank Of Canada lowered their price objective on Zynex from $4.00 to $3.00 and set a "sector perform" rating for the company in a research report on Tuesday.

Hedge Funds Weigh In On Zynex

A hedge fund recently raised its stake in Zynex stock. Goldman Sachs Group Inc. lifted its holdings in Zynex Inc. (NASDAQ:ZYXI - Free Report) by 118.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 170,718 shares of the company's stock after buying an additional 92,463 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.56% of Zynex worth $376,000 as of its most recent SEC filing. 29.68% of the stock is currently owned by institutional investors and hedge funds.

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.